Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report

[1]  K. Reynolds,et al.  The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity , 2021, JACC. CardioOncology.

[2]  G. Curigliano,et al.  Recent eUpdate on cabozantinib and nivolumab for first-line clear cell renal cancer to the ESMO Clinical Practice Guidelines on Renal Cell Carcinoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. D. de Boer,et al.  Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues , 2020, Current Oncology Reports.

[4]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[5]  Deepak L. Bhatt,et al.  Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[6]  J. Jeudy,et al.  Assessment of Myocarditis: Cardiac MR, PET/CT, or PET/MR? , 2019, Current Cardiology Reports.

[7]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[8]  E. Lipson,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors , 2019, Cardiovascular research.

[9]  J. Larkin,et al.  Immune checkpoint inhibitors and cardiovascular toxicity. , 2018, The Lancet. Oncology.

[10]  R. Sullivan,et al.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.

[11]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Takayama,et al.  Plasma brain natriuretic peptide levels are elevated in patients with cancer , 2017, PloS one.

[13]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[14]  Guido Strunk,et al.  Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality , 2015, Heart.

[15]  L. Cooper,et al.  Update on myocarditis. , 2012, Journal of the American College of Cardiology.

[16]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .

[17]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[18]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[19]  P. Keeling,et al.  A prospective case-control study of antibodies to coxsackie B virus in idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.